International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 121-128
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |
FDG-PET Scan in Colorectal Cancer
Faysal DANE1, Fuat DEDE2, Beste M. ATASOY3
1Marmara Üniversitesi, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Tıbbi Onkoloji BilimDalı, İSTANBUL
2Marmara Üniversitesi, Tıp Fakültesi, Nükleer Tıp Ana Bilim Dalı, İSTANBUL
3Marmara Üniversitesi, Tıp Fakültesi, Radyasyon Onkolojisi Ana Bilim Dalı, İSTANBUL
Keywords: FDG, PET/CT, Colorectal cancer
[18F] Fluorodeoxyglucose (FDG) positron emission tomography (PET) is a useful imaging tool in the management of patients with colorectal carcinoma. This technique has an essential role in the staging of patients prior to surgical resection of recurrence and metastases, in the localization of recurrence in patients with an unexplained rise in serum carcinoembryonic antigen, in the assessment of residual masses after treatment, in determining tumor response to therapy in neo-adjuvant settings, and in evaluating colorectal cancer prognosis. It is possible to measure and visualize metabolic changes in cancer cells via FDG-PET. Combined PET/CT scans permit exact localization with anatomical criteria of the hypermetabolic FDG avid malignant lesions. This review aims to outline the current and future role of FDG-PET in the field of colorectal cancer.
Faysal DANE1, Fuat DEDE2, Beste M. ATASOY3
1Marmara Üniversitesi, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Tıbbi Onkoloji BilimDalı, İSTANBUL
2Marmara Üniversitesi, Tıp Fakültesi, Nükleer Tıp Ana Bilim Dalı, İSTANBUL
3Marmara Üniversitesi, Tıp Fakültesi, Radyasyon Onkolojisi Ana Bilim Dalı, İSTANBUL
Keywords: FDG, PET/CT, Colorectal cancer
[18F] Fluorodeoxyglucose (FDG) positron emission tomography (PET) is a useful imaging tool in the management of patients with colorectal carcinoma. This technique has an essential role in the staging of patients prior to surgical resection of recurrence and metastases, in the localization of recurrence in patients with an unexplained rise in serum carcinoembryonic antigen, in the assessment of residual masses after treatment, in determining tumor response to therapy in neo-adjuvant settings, and in evaluating colorectal cancer prognosis. It is possible to measure and visualize metabolic changes in cancer cells via FDG-PET. Combined PET/CT scans permit exact localization with anatomical criteria of the hypermetabolic FDG avid malignant lesions. This review aims to outline the current and future role of FDG-PET in the field of colorectal cancer.
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |